Skip to main content
. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622

Fig. 1.

Fig. 1

Study cohort. HCC, hepatocellular carcinoma; ICIs, immune checkpoint inhibitors; VEGF, vascular endothelial growth factor; TKIs, tyrosine kinase inhibitors; TACE, transarterial chemoembolization; BCLC, Barcelona Clinic Liver Cancer; TACE-ICI-VEGF, TACE with ICIs plus anti-VEGF antibody/TKIs; ICI-VEGF, ICIs plus anti-VEGF antibody/TKIs.